← Back to headlines
Truist Reaffirms 'Buy' Ratings for Meta Platforms and Boston Scientific
Truist has reiterated its 'Buy' rating for both Meta Platforms (META) and Boston Scientific (BSX). The firm set a price target of $840 for Meta Platforms.
13 Jun, 17:59 — 13 Jun, 17:59
Sources
Showing 1 of 1 sources
